Fumonisin B 1 (FB 1 ) is a mycotoxin produced by Fusarium verticillioides found on corn and corn-based foods. It causes equine leukoencephalomalacia, porcine pulmonary edema, and liver and kidney damage in most animal species. Fumonisin B 1 perturbs sphingolipid metabolism by inhibiting ceramide synthase activity, leading to the production of cell signaling factors including tumor necrosis factor a (TNF-a). The signal pathways of TNF-a are important factors in the pathogenesis of FB 1 hepatotoxicity. In the present study, female BALB/c mice were treated daily with 750 mg/kg silymarin by gavage and 2.25 mg/kg FB 1 subcutaneously for 3 days. Then, 1 day after the last FB 1 injection, the mice were euthanized and blood and tissues were sampled for analyses. Silymarin significantly diminished FB 1 -induced elevation of plasma alanine aminotransferase and aspartate aminotransferase activities and the number of apoptotic hepatocytes, while it augmented hepatocyte proliferation indicated by an increase in proliferating cells. Silymarin dramatically potentiated FB 1 -induced accumulation of free sphinganine and sphingosine in both liver and kidney. Silymarin itself slightly increased expression of hepatic TNF-a; however, it prevented the FB 1 -induced increases in TNF-a, TNF receptor 1, TNF receptor-associated apoptosis-inducing ligand, lymphotoxin b, and interferon g. The induction of transforming growth factor b1 expression in liver following FB 1 treatment was not affected by silymarin. These findings suggest that silymarin protected against FB 1 liver damage by inhibiting biological functions of free sphingoid bases and increasing cellular regeneration.
Fumonisins are a group of mycotoxins produced by Fusarium verticillioides (5F. moniliforme) found on corn worldwide (World Health Organization, 2000) . Fumonisin B 1 (FB 1 ), the most abundant fumonisin, causes equine leukoencephalomalacia (Marasas, 2001 ) and porcine pulmonary edema (Haschek et al., 2001; Marasas, 2001) . A high incidence of human esophageal cancer in southern Africa and China was epidemiologically associated with the consumption of fumonisin-contaminated foods (Marasas, 2001) . Fumonisin B 1 is a hepatic and renal carcinogen in rats and a hepatic carcinogen in mice (Gelderblom et al., 1991; Howard et al., 2001) . Fumonisins are hepatotoxic and nephrotoxic in laboratory animals (Sharma et al., 1997; Voss et al., 2001) . The toxic effects of FB 1 at the cellular level consist of a mixture of both necrosis and apoptosis Lemmer et al., 1999) .
Fumonisins are structurally similar to free sphingoid bases. They inhibit ceramide synthase Wang et al., 1991) , which results in the accumulation of free sphinganine and, subsequently,sphingosine,leadingtoadepletion ofceramide and complex sphingolipids Riley et al., 1993 Riley et al., , 1997 Wang et al., 1991; Yoo et al., 1996) . An accumulation of free sphingoid bases promotes the formation of other sphingolipidmetabolitessuch assphingoidbase-1-phosphatesanddownstream metabolites . Toxicity of FB 1 is well correlated with the accumulation of free sphinganine Tsunoda et al., 1998; Yoo et al., 1996) and the depletion of complex sphingolipids (Tsunoda et al., 1998; Yoo et al., 1996) .
Fumonisin B 1 induces the expressions of various cytokines including tumor necrosis factor a (TNF-a) in mice . It has been established that TNF-a signaling pathways modulate FB 1 toxicity both in vivo and in vitro. Fumonisin B 1 hepatotoxicity was reduced in mice lacking either TNF receptor (TNFR) 1 (P55) or TNFR 2 (P75) (Sharma et al., 2000a ). Transfection of a baculovirus gene, inhibitor of apoptosis (IAP), an inhibitor of TNF-a-induced cell death, protected renal cells and fibroblasts from FB 1 -induced apoptosis (CiacciZanella and Jones, 1999; Jones et al., 2001) . Expression of TNFR-associated protein (TRAP) 2 was induced in FB 1 -sensitive CV-1 cells but repressed in FB 1 -resistant COS cells following FB 1 treatment , supporting that TNF-a signal pathways are involved in FB 1 toxicity. The signaling cascade in TNF-a pathways results in apoptosis upon activation of different downstream signaling molecules after the binding of TNF-a to TNFRs (Bradham et al., 1998) .
Silymarin, an extract from seeds and fruits of Silybum marianum, is a mixture of flavonoid isomers such as silibinin, isosilibinin, silidianin, and silichristin. Silymarin suppresses the activation of caspases and nuclear factor (NF-) kB in various cell types following TNF-a treatment (Manna et al., 1999) . Silymarin or silibinin, a major active component of silymarin, inhibited the production of cytokines, e.g., TNF-a, interferon (IFN) g, interleukin (IL)-2, IL-4, IL-6, and IL-8, in mouse liver in response to concanavalin A-induced, T cell-dependent liver injury (Schümann et al., 2003) . Suppression of NF-kB activation by silymarin probably accounts for its inhibitory effects on cytokine production (Manna et al., 1999; Schümann et al., 2003) . We recently reported that, in contrast to increasing TNF-a expression by itself in LLC-PK 1 cells, silymarin prevented FB 1 -induced overexpression of this cytokine and effectively protected LLC-PK 1 cells from FB 1 cytotoxicity (He et al., 2002) . Silymarin has been recommended in the prevention of alcoholic liver disease (Saller et al., 2001) , and it protected against injury from various other hepatotoxicants such as carbon tetrachloride, paracetamol (Saller et al., 2001) , and concanavalin A (Schümann et al., 2003) .
In the current study, the protective effect of silymarin on FB 1 hepatotoxicity was investigated in female mice. Results demonstrated that silymarin protected mice from FB 1 -induced liver injury, as indicated by reduced activities of circulating alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and number of apoptotic hepatocytes. Silymarin caused liver regeneration, as shown by an increased number of proliferating cells in liver. Fumonisin-induced expressions of proinflammatory cytokines were effectively prevented by pretreatment with silymarin.
MATERIALS AND METHODS
Chemicals. Fumonisin B 1 (purity 498%) was obtained from Programme on Mycotoxins and Experimental Carcinogenesis (PROMEC, Tygerberg, South Africa). Silymarin (product number: 254924), a mixture of toxifolin (4%), silichristin (27.9%), silidianin (2.9%), silybin A (19.3%), silybin B (31.3%), isosilybin A (8.2%), and isosilybin B (2.3%), determined by high-performance liquid chromatography (HPLC)/277 nm detection, and all other reagents were purchased from Sigma-Aldrich Corp. (St. Louis, MO), unless otherwise stated.
Animals. Six-week-old female BALB/c mice weighing about 22 g were obtained from Harlan Laboratories (Indianapolis, IN). They were acclimated for 1 week before dosing under controlled environmental conditions at 23 C and 65% relative humidity with a 12-h light/dark cycle. Feed and water were available ad libitum. Mice were treated according to the Public Health Service Policy on Humane Care and Use of Laboratory Animals and the Institutional Animal Care and Use Committee approved treatment.
Treatment. Animals were divided randomly into four groups with five mice each, and treated orally with water or silymarin by gavage once daily (750 mg/kg) at 16 h before FB 1 dosing. The mice were given three daily subcutaneous injections of either phosphate-buffered saline (PBS) or 2.25 mg/kg of FB 1 in PBS. The protocol had been proved to produce consistent liver damage in female mice exposed to FB 1 in our laboratory.
One day after the final FB 1 treatment, mice were sacrificed by decapitation. Blood was collected in heparinzed tubes, and plasma was subsequently isolated for analysis of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Livers and kidneys were collected from each animal, and aliquots were fixed immediately in neutral 10% formalin or quickly frozen in liquid nitrogen and stored at À85 C until analysis.
Analysis of liver enzymes in plasma. Activities of plasma ALT and AST were determined using a Hitachi 912 Automatic Analyzer (Roche Diagnostics, Indianapolis, IN).
Terminal deoxynucleotidyl transferase-(TdT-) mediated dUTP nick-end labeling (TUNEL) assay for apoptosis. Liver tissue sections (5 mm) were prepared and subjected to dUTP nick-end labeling by TdT with a peroxidasebased, in situ Cell Death Detection kit (Roche Diagnostics), as described previously (Sharma et al., 2003a) . The stained apoptotic cells were counted under a light microscope and normalized to the unit area, as described previously (Sharma et al., 1997) .
Immunohistochemistry for proliferating cellular nuclear antigen (PCNA) assay. Hepatocyte proliferation was determined by analysis of PCNA in formalin-fixed, paraffin-embedded liver tissues, as described previously (Sharma et al., 2003a,b) . The number of PCNA-positive cells were counted under a microscope and normalized to the unit area, as described previously (Sharma et al., 1997) . A few other cells beside hepatocytes, such as endothelial cells, were labeled with PCNA, but only PCNA-positive hepatocytes were counted.
Histology. Liver specimens were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned (4 to 5 mm), and stained with hematoxylin and eosin (H&E). The tissues were examined under a microscope in a random order and without knowledge of animal or group.
Sphingolipid analysis. Free sphingosine and sphinganine of liver and kidney in base-treated lipid extracts were determined by HPLC using a modification of the extraction methods described previously (Merrill et al., 1988) . Sphingoid bases were quantitated based on the recovery of a C 20 -sphinganine standard (D-erythro-C 20 -dihydro-sphingosine; Matreya Inc., Pleasant Gap, PA). The HPLC apparatus and derivation procedure were similar to those described previously (Merrill et al., 1988) , except the fluorescence detector used in this study was Luminescence Spectrometer LS30 (Perkin-Elmer Inc., Norwalk, CT).
Assay for the activity of serine palmitoyltransferase (SPT). The SPT activity in liver and kidney was analyzed using the method described by Williams et al. (1984) with minor modification. Briefly, the frozen tissues were homogenized in homogenization buffer (50 mM N-[2-hydroxyethyl]piperazine-N 0 -[2-ethanesulfonic acid], 5 mM DL-dithiothreitol, 10 mM ethylenediaminetetraacetic acid, and 0.25 M sucrose [pH 7.4]), and the homogenate was centrifuged at 30,000 3 g for 30 min. Aliquots of 100 mg protein in the supernatant were used for analysis of SPT activity, as described previously (He et al., 2004; Williams et al., 1984) . The protein content was determined by Bio-Rad Bradford reagent according to the manufacturer's protocol (Bio-Rad Laboratories, Hercules, CA).
RNase protection assay (RPA) for selected gene expression. Total RNA from liver tissue was extracted with TRI reagents (Molecular Research Center, Cincinnati, OH). An aliquot part of 50 mg RNA was used for RPA using RiboQuant RPA starter kit (BD Biosciences, San Diego, CA), as described previously (Sharma et al., 2003b) . The relative gene expression was normalized against ribosomal protein L32.
Statistical analysis. Results are presented as mean 6 standard error (SE). Data were analyzed by two-way analysis of variance (ANOVA) followed by Duncan's multiple range test, unless otherwise stated. In selected cases where unequal variances of different groups were obvious, the Wilcoxon rank sum test was employed. The level of p 5 0.05 was considered significant.
RESULTS
Silymarin Reduced FB 1 -Induced Increases of Plasma ALT and AST Activities
Following FB 1 treatment, the plasma activity of ALT increased to 33-fold as much as that of control; silymarin significantly reduced the FB 1 -induced elevation of ALT by 70% (Fig. 1A) . Silymarin treatment also decreased FB 1 -induced plasma AST elevation to the control level (Fig. 1B) . Silymarin alone did not alter plasma activities of ALT and AST.
Silymarin Diminished FB 1 -Induced Hepatocyte Apoptosis and Stimulated Cell Proliferation
No apoptotic cells were observed in control or silymarin alone-treated mice. Similar to the changes seen in plasma ALT and AST activities, the number of apoptotic hepatocytes as well as the incidence of apoptosis in response to FB 1 treatment was significantly reduced by silymarin (Table 1) .
In response to the injury caused by FB 1 , the liver underwent a compensatory regeneration indicated by an increase in the number of PCNA-positive hepatocytes. The number of PCNApositive cells was increased by 6-fold in silymarin 1 FB 1 -treated mice compared to FB 1 alone-treated mice (Table 1 ). The appearance of PCNA-positive cells in FB 1 -treated mouse liver was similar to that reported previously (Sharma et al., 2003b) .
The effect of 3-day FB 1 treatment on mouse liver was limited to the presence of scattered apoptotic hepatocytes, characterized by the presence of small round to ovoid cells and occasional mitotic figures. No swollen cells indicative of oncotic changes were observed. The cells undergoing apoptosis were usually present as single cells with no leukocytic infiltration and were surrounded by normal cells. The architecture of liver tissue was not influenced by either treatment, and treatment with silymarin provided no distinguishable differences from livers of control animals. Figure 2 shows both an H&E-stained and a TUNELstained liver section from an FB 1 -treated mouse. The extent of damage was corroborated with ALT and AST activities and enumeration of apoptotic cells in tissue sections by TUNEL assay. 
FIG. 1.
The effects of silymarin (S) on fumonisin B 1 (FB 1 )-induced increases in plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities. Female BALB/c mice were treated daily with 750 mg/kg silymarin by gavage and for 3 days with 2.25 mg/kg FB 1 subcutaneously. One day after the last FB 1 treatment, the animals were sacrificed and plasma was used for analysis of ALT and AST. Data are presented as mean 6 SE (n 5 5). Different letters indicate statistical differences at p 5 0.05.
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The Effect of Silymarin on FB 1 -Induced Accumulation of Free Sphingoid Bases
By inhibiting the activity of ceramide synthase, FB 1 has been shown to cause the accumulation of free sphinganine, a precursor of dihydroceramide and ceramide Wang et al., 1991) . Consistent with these studies, FB 1 significantly increased the level of hepatic free sphinganine but not sphingosine (Figs. 3A and 3B) . Unexpectedly, the levels of free sphinganine and sphingosine in liver were significantly higher in silymarin 1 FB 1 -treated mice than those in FB 1 alone-treated mice, whereas silymarin alone did not alter concentrations of free sphingoid bases (Figs. 3A and 3B ).
To investigate whether or not the potentiation of free sphingoid bases accumulation by silymarin in FB 1 exposure was specific for liver, we measured concentrations of renal free sphinganine and sphingosine. The results demonstrated, as observed in liver, that the content of kidney free sphingoid bases was significantly higher in mice treated with a combination of silymarin and FB 1 than in FB 1 alone-treated mice (Figs. 3C  and 3D ).
Silymarin Prevented FB 1 -Induced Activation of SPT in Liver
As the overall content of free sphingoid bases was much higher in silymarin-pretreated mice in response to FB 1 , we measured the activity of SPT, the first enzyme in the pathway of de novo biosynthesis of sphingolipid (Hannun et al., 2001 ). Compared to the controls, a significant increase in the activity of hepatic SPT was observed in FB 1 alone-treated mice (Table 2) . Silymarin significantly decreased the activity of liver SPT to a similar extent as in mice treated with either silymarin or silymarin 1 FB 1 .
The activity of SPT in kidney was not altered upon FB 1 treatment (Table 2) . Silymarin decreased kidney SPT activity compared to the controls, but it did not significantly change the SPT activity in kidney following FB 1 exposure ( Table 2 ).
The Effects of Silymarin on the Expressions of Selected
Genes in Response to FB 1 Treatment FB 1 treatment increased the expressions of hepatic genes for selected TNF-a superfamily, namely TNF-a, TNFR1, TNF receptor-associated apoptosis-inducing ligand (TRAIL), and lymphotoxin (LT) b (Fig. 4) . Silymarin moderately increased the expression of TNF-a in liver; however, it completely prevented FB 1 -induced increases of these genes (Fig. 4) .
The expressions of IFNg and transforming growth factor (TGF) b1 in liver were significantly increased in response to FB 1 treatment (Fig. 5) . The induction of IFNg expression following FB 1 exposure was completely reversed by silymarin. Silymarin partially diminished FB 1 -induced overexpression of TGFb1 by 17%. The increased expression of hepatic TGFb1 mRNA in silymarin 1 FB 1 -treated mice was not significantly different than that in PBS-treated mice (Fig. 5) . The increased expression of hepatic TGFb1 mRNA in silymarin 1 FB 1 -treated mice was also not significantly different than that in mice treated with FB 1 alone.
Neither FB 1 nor silymarin altered the expressions of Fas signaling factors such as Fas ligand, Fas, Fas-associated death domain (FADD), and Fas-associated phosphatase (FAP, data not shown).
DISCUSSION
This study showed that silymarin prevented FB 1 -induced liver injury and the overexpressions of selected genes for TNF-a superfamily and IFNg. FB 1 increased free sphingoid bases in tissues via the inhibition of ceramide synthase Wang et al., 1991) . Free sphingoid bases could mediate cell death following FB 1 treatment (Schmelz et al., 1998; Tolleson et al., 1999) . In contrast to its inhibitory effects on liver damage and selected gene induction, silymarin dramatically increased FB 1 -induced accumulation of free sphingoid bases.
The FB 1 -induced alterations in mouse liver were similar to those reported previously employing similar protocols (Sharma et al., 1997 (Sharma et al., , 2003a . The only difference in treatments was the duration (3 vs. 5 days in former reports) and gender (females in the current experiments). Exposure of mice to FB 1 caused the appearance of apoptotic cells in liver with no other noticeable alterations. The PCNA-positive cells were also increased in FB 1 -treated mice. In the group treated with both silymarin and FB 1 , the number of apoptotic (TUNEL-positive) cells was decreased and the number of proliferating (PCNA-positive) cells was increased. These changes suggested that silymarin both decreased the cellular damage and increased the regeneration of liver when coadministered with FB 1 .
Silymarin has been reported to stimulate enzymatic activity of DNA-dependent RNA polymerase 1 and subsequent biosynthesis of RNA and protein, resulting in DNA biosynthesis and cell proliferation (Sonnenbichler and Zetl, 1986) . The stimulatory effect of silymarin on liver regeneration was observed only in damaged livers (Sonnenbichler and Zetl, 1986) . These findings indicate that silymarin increases regeneration potency of damaged liver tissues. Consistent with these studies, we demonstrated that silymarin increased proliferating hepatocytes in response to FB 1 -induced cell death without modulation of cell proliferation in normal livers (Table 1 ). The capability of silymarin to stimulate regeneration activity of liver tissue in FB 1 intoxication could partly account for the observed hepatoprotective actions.
Silymarin has clinical applications in the treatment of cirrhosis, ischemic injury, and toxic hepatitis induced by various toxins such as ethanol, carbon tetrachloride, acetaminophen, organic solvents, and toxic mushroom (Saller et al., 2001) . The pharmacological properties of silymarin involve the regulation of cell membrane permeability and integrity, inhibition of leukotriene, reactive oxygen species scavenging, suppression of NF-kB activity, depression of protein kinases, and collagen production (Saller et al., 2001) . Silymarin is able to reduce the cellular uptake of xenobiotics including mushroom poisons (Saller et al., 2001) ; it has been recently shown that silymarin can potentiate doxorubicin cytotoxicity by inhibiting P-glycoprotein-mediated drug efflux (Zhang and Morris, 2003) .
In response to FB 1 , mice cotreated with silymarin had a greater accumulation of free sphingoid bases in both liver and kidney than those exposed only to FB 1 (Fig. 3) . It has been suggested that the hydrophilic FB 1 entered cells in an LLC-PK 1 cell model through passive diffusion (Enongene et al., 2002) . Moreover, we previously reported that mice lacking p-glycoprotein genes exhibited a similar response to FB 1 hepatoand nephrotoxicity as their wild-type counterparts, suggesting little role of multidrug transport system in FB 1 toxicity (Sharma et al., 2000b) . Therefore, the effect of silymarin on P-glycoprotein would not account for its protection against FB 1 toxicity. The mechanisms by which silymarin potentiates FB 1 -induced accumulation of free sphingoid bases are currently unknown. The activity of SPT was not increased in response to silymarin or silymarin 1 FB 1 , suggesting that silymarin potentiation of FB 1 -induced free sphingoid bases accumulation in liver and kidney tissues is not due to increased de novo biosynthesis. Sphingosine kinase is responsible for the conversion of free sphingoid bases to their 1-phosphate metabolites (Hannun et al., 2001) . It is unclear whether or not silymarin affects the activity of sphingosine kinase or efflux of intracellular free sphingoid bases from cells. Silymarin is able to stabilize cellular membrane (Saller et al., 2001) . The higher levels of free sphinganine and sphingosine in silymarin 1 FB 1 -treated mouse livers and kidneys might result from reduced efflux of intracellular free sphingoid bases as a consequence of inhibiting cellular membrane damage.
Free sphingoid bases are proapoptotic and cell growth inhibitory . The disruption of sphingolipid metabolism resulting from the inhibition of ceramide synthase by FB 1 is believed responsible for FB 1 toxicity. The accumulation of free sphinganine and depletion of complex sphingolipid correlated with FB 1 toxicity in vitro and in vivo Tsunoda et al., 1998; Yoo et al., 1996) . The inhibition of SPT prevented the accumulation of free sphinganine and reversed FB 1 cytotoxicity in various cell types (He et al., 2002; Schmelz et al., 1998; Tolleson et al., 1999; Yoo et al., 1996) . In the present study, the FB 1 -induced elevations of serum ALT and AST and apoptotic hepatocytes were dramatically decreased by silymarin, though greater accumulation of hepatic free sphingoid bases was observed in cotreatment with silymarin and FB 1 . These results suggest that silymarin protects FB 1 toxicity through blocking the actions of free sphingoid bases. The ability of silymarin to preserve the integrity of cellular and mitochodrial membrane could in part explain its protective effects on FB 1 hepatotoxicity.
Fumonisin has been shown to increase the expressions of many cytokines and apoptotic signaling factors . Silymarin has been shown to protect liver from hepatotoxin injury by inhibiting the production of TNF-a, IFNg, IL-2, and IL-4 as a consequence of blocking hepatic NF-kB activation (Schümann et al., 2003) . Consistent with these findings, we observed in the present study that silymarin reversed FB 1 induction of TNF-a, TNFR1, TRAIL, LT b, and IFNg (Figs. 4 and 5). Silymarin also has been shown to repress TNF-ainduced activation of NF-kB and apoptosis in various cell types (Manna et al., 1999) . Either TNFR1 or TNFR2 knockout mice exhibited less sensitivity to FB 1 liver injury compared to their wild-type counterparts (Sharma et al., 2000a . It has been shown that transfection of a baculovirus gene, an important inhibitor of apoptosis (IAP) in TNF-a-induced apoptosis pathway, protected CV-1 cells from FB 1 -induced activation of caspase 8 and apoptosis (Ciacci-Zanella and Jones, 1999; . These studies supported the idea that the signal pathways of TNF-a play an important role in the pathogenesis of FB 1 . Lacking IFNg has also been shown to be less responsive to FB 1 treatment (Sharma et al., 2003a) . Silymarin-reversed FB 1 overexpressions of signal factors in TNF-a superfamily and IFNg could in part account for its protective role in FB 1 hepatotoxicity.
In conclusion, we have clearly demonstrated that silymarin plays a protective role in FB 1 hepatotoxicity in a mouse model. These findings suggest a therapeutic potential of silymarin in fumonisin liver injury in humans or animals exposed to fumonisin-producing, fungus-contaminated feeds. The efficacy of silymarin in the protection from liver damage after long-term exposure to the mycotoxin still needs to be studied.
